Theravance Biopharma, Inc. (NASDAQ:TBPH) has received an average rating of “Hold” from the eleven ratings firms that are covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $42.17.
A number of research analysts recently commented on the company. Cantor Fitzgerald set a $55.00 price target on Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday. Evercore ISI assumed coverage on Theravance Biopharma in a report on Wednesday. They issued an “outperform” rating and a $45.00 price target for the company. BidaskClub downgraded Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. ValuEngine raised Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Leerink Swann set a $47.00 price target on Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday, May 10th.
In other news, CEO Rick E. Winningham bought 10,000 shares of Theravance Biopharma stock in a transaction on Friday, August 11th. The shares were bought at an average price of $24.50 per share, with a total value of $245,000.00. Following the acquisition, the chief executive officer now directly owns 866,377 shares in the company, valued at approximately $21,226,236.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Henrietta Fore bought 6,000 shares of Theravance Biopharma stock in a transaction on Friday, August 11th. The shares were purchased at an average cost of $23.99 per share, for a total transaction of $143,940.00. Following the acquisition, the director now owns 24,000 shares in the company, valued at $575,760. The disclosure for this purchase can be found here. Corporate insiders own 6.10% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. QS Investors LLC purchased a new position in Theravance Biopharma during the second quarter worth approximately $100,000. Ameritas Investment Partners Inc. increased its position in Theravance Biopharma by 1,494.3% in the first quarter. Ameritas Investment Partners Inc. now owns 3,635 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 3,407 shares in the last quarter. Aperio Group LLC purchased a new position in Theravance Biopharma during the second quarter worth approximately $205,000. BNP Paribas Arbitrage SA increased its position in Theravance Biopharma by 570.7% in the second quarter. BNP Paribas Arbitrage SA now owns 5,151 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 4,383 shares in the last quarter. Finally, Amalgamated Bank purchased a new position in Theravance Biopharma during the second quarter worth approximately $214,000. 82.77% of the stock is currently owned by institutional investors.
Shares of Theravance Biopharma (TBPH) opened at 27.66 on Friday. The company’s 50-day moving average price is $34.24 and its 200 day moving average price is $35.37. The stock’s market cap is $1.49 billion. Theravance Biopharma has a 1-year low of $23.15 and a 1-year high of $43.44.
TRADEMARK VIOLATION WARNING: “Theravance Biopharma, Inc. (TBPH) Given Consensus Recommendation of “Hold” by Brokerages” was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/08/18/theravance-biopharma-inc-tbph-given-consensus-recommendation-of-hold-by-brokerages.html.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
What are top analysts saying about Theravance Biopharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Theravance Biopharma Inc. and related companies.